These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 22882002)

  • 21. A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells.
    Hayashi H; Asano R; Tsumoto K; Katayose Y; Suzuki M; Unno M; Kodama H; Takemura S; Yoshida H; Makabe K; Imai K; Matsuno S; Kumagai I; Kudo T
    Cancer Immunol Immunother; 2004 Jun; 53(6):497-509. PubMed ID: 14648071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence.
    Mazor Y; Sachsenmeier KF; Yang C; Hansen A; Filderman J; Mulgrew K; Wu H; Dall'Acqua WF
    Sci Rep; 2017 Jan; 7():40098. PubMed ID: 28067257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a bispecific antibody tetramerized through hetero-associating peptides.
    Osaki T; Fujisawa S; Kitaguchi M; Kitamura M; Nakanishi T
    FEBS J; 2015 Nov; 282(22):4389-401. PubMed ID: 26337767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics.
    Steffen AC; Wikman M; Tolmachev V; Adams GP; Nilsson FY; Ståhl S; Carlsson J
    Cancer Biother Radiopharm; 2005 Jun; 20(3):239-48. PubMed ID: 15989469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody.
    Zheng S; Moores S; Jarantow S; Pardinas J; Chiu M; Zhou H; Wang W
    MAbs; 2016; 8(3):551-61. PubMed ID: 26761634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimized linker sequences for the expression of monomeric and dimeric bispecific single-chain diabodies.
    Völkel T; Korn T; Bach M; Müller R; Kontermann RE
    Protein Eng; 2001 Oct; 14(10):815-23. PubMed ID: 11739902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds.
    Malm M; Frejd FY; Ståhl S; Löfblom J
    MAbs; 2016 Oct; 8(7):1195-1209. PubMed ID: 27532938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bispecific Antibody Conjugated Manganese-Based Magnetic Engineered Iron Oxide for Imaging of HER2/neu- and EGFR-Expressing Tumors.
    Wu SC; Chen YJ; Wang HC; Chou MY; Chang TY; Yuan SS; Chen CY; Hou MF; Hsu JT; Wang YM
    Theranostics; 2016; 6(1):118-30. PubMed ID: 26722378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis of bispecific antibodies using genetically encoded unnatural amino acids.
    Kim CH; Axup JY; Dubrovska A; Kazane SA; Hutchins BA; Wold ED; Smider VV; Schultz PG
    J Am Chem Soc; 2012 Jun; 134(24):9918-21. PubMed ID: 22642368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Construction of a Novel Bispecific Antibody to Enhance Antitumor Activity against Lung Cancer.
    Yin W; Zhu J; Gonzalez-Rivas D; Okumura M; Rocco G; Pass H; Jiang G; Yang Y
    Adv Mater; 2018 Dec; 30(51):e1805437. PubMed ID: 30345557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new prodrug form of Affibody molecules (pro-Affibody) is selectively activated by cancer-associated proteases.
    Sandersjöö L; Jonsson A; Löfblom J
    Cell Mol Life Sci; 2015 Apr; 72(7):1405-15. PubMed ID: 25287047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunology. Two-in-one designer antibodies.
    Parren PW; Burton DR
    Science; 2009 Mar; 323(5921):1567-8. PubMed ID: 19299606
    [No Abstract]   [Full Text] [Related]  

  • 33. World Bispecific Antibody Summit, September 27-28, 2011, Boston, MA.
    Dhimolea E; Reichert JM
    MAbs; 2012; 4(1):4-13. PubMed ID: 22327426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs.
    Els Conrath K; Lauwereys M; Wyns L; Muyldermans S
    J Biol Chem; 2001 Mar; 276(10):7346-50. PubMed ID: 11053416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bispecific antibody generated with sortase and click chemistry has broad antiinfluenza virus activity.
    Wagner K; Kwakkenbos MJ; Claassen YB; Maijoor K; Böhne M; van der Sluijs KF; Witte MD; van Zoelen DJ; Cornelissen LA; Beaumont T; Bakker AQ; Ploegh HL; Spits H
    Proc Natl Acad Sci U S A; 2014 Nov; 111(47):16820-5. PubMed ID: 25385586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Construction of a circularly connected VHH bispecific antibody (cyclobody) for the desirable positioning of antigen-binding sites.
    Hemmi S; Asano R; Kimura K; Umetsu M; Nakanishi T; Kumagai I; Makabe K
    Biochem Biophys Res Commun; 2020 Feb; 523(1):72-77. PubMed ID: 31831177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective Targeting of Cells via Bispecific Molecules That Exploit Coexpression of Two Intracellular Proteins.
    Dunyak BM; Nakamura RL; Frankel AD; Gestwicki JE
    ACS Chem Biol; 2015 Nov; 10(11):2441-7. PubMed ID: 26322864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fabs-in-tandem immunoglobulin is a novel and versatile bispecific design for engaging multiple therapeutic targets.
    Gong S; Ren F; Wu D; Wu X; Wu C
    MAbs; 2017 Oct; 9(7):1118-1128. PubMed ID: 28692328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SPR-based assays enable the full functional analysis of bispecific molecules.
    Meschendoerfer W; Gassner C; Lipsmeier F; Regula JT; Moelleken J
    J Pharm Biomed Anal; 2017 Jan; 132():141-147. PubMed ID: 27721070
    [TBL] [Abstract][Full Text] [Related]  

  • 40. "Two-in-One" approach for bioassay selection for dual specificity antibodies.
    Lee HY; Schaefer G; Lesaca I; Lee CV; Wong PY; Jiang G
    J Immunol Methods; 2017 Sep; 448():74-79. PubMed ID: 28579366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.